Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential
Abstract
Background and Objective Finasteride 5 mg is a well-established therapy for benign prostatic hyperplasia (BPH). Lower doses, such as finasteride 1 mg—commonly prescribed for androgenic alopecia—also produce measurable suppression of dihydrotestosterone (DHT) and prostate-specific antigen (PSA). This review examines the available evidence related to finasteride 1 mg with respect to prostate biology, safety, and its theoretical potential in modifying BPH risk when initiated earlier in life and its hypothesis-generating potential for preventive use. Methods A structured review of PubMed, EMBASE, and the Cochrane Library from January 1990 through January 2026 was performed to identify studies evaluating finasteride 1 mg with prostate-relevant biologic or surrogate outcomes, including PSA suppression and androgen modulation. Pharmacodynamic dose-response studies were reviewed, and landmark randomized controlled trials (RCTs) of finasteride 5 mg in men with BPH were included for clinical context regarding established prostate volume, symptoms, and progression outcomes. Key Content and Findings Observational and secondary analyses evaluating long-term exposure to finasteride 1 mg demonstrate consistent biologic effects on prostate-related pathways, most notably suppression of serum PSA. Prostate volume, lower urinary tract symptoms (LUTS), and progression-related outcomes were not predefined primary endpoints in available studies evaluating finasteride 1 mg, and direct evidence…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.